March 30, 2022
CHMP Recommends EU Approval of Roche’s Polivy Combination for People with Previously Untreated Diffuse Large B-cell Lymphoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Roche’s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL).